secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2022-04-08T23:59:59+00:00
Accession:  0001193125-22-100388
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics EVP/Chief of Clinical Affairs Morosini resigns; advisor through May 5
--------------------------------------------------------------------------------

- Deborah Morosini resigned as EVP and Chief of Clinical Affairs effective April 6, 2022.
- She will serve as Strategic Advisor to the President until May 5, 2022, then employment ends.
- Severance includes 3 months base salary and 3 months COBRA premium payments.
- She may provide consulting services from May 5 to November 4, 2022 on an as-needed basis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312522100388/0001193125-22-100388-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312522100388/d292059d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-100388

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer